| Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach M Fischer, B Sipe, YW Cheng, E Phelps, N Rogers, S Sagi, M Bohm, H Xu, ... Gut microbes 8 (3), 289-302, 2017 | 192 | 2017 |
| Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta‐analysis of randomized controlled trials SV Sagi, S Mittal, KS Kasturi, GK Sood Journal of gastroenterology and hepatology 25 (5), 880-885, 2010 | 165 | 2010 |
| Open: Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium N Narula, F Peerani, J Meserve, G Kochhar, K Chaudrey, J Hartke, ... Official journal of the American College of Gastroenterology| ACG 113 (9), 1345, 2018 | 143 | 2018 |
| Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases J Meserve, S Aniwan, JL Koliani-Pace, P Shashi, A Weiss, D Faleck, ... Clinical Gastroenterology and Hepatology 17 (8), 1533-1540. e2, 2019 | 84 | 2019 |
| Narrow-band imaging versus white light for the detection of proximal colon serrated lesions: a randomized, controlled trial DK Rex, R Clodfelter, F Rahmani, H Fatima, TN James-Stevenson, ... Gastrointestinal endoscopy 83 (1), 166-171, 2016 | 75 | 2016 |
| Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort … JR Allegretti, M Fischer, SV Sagi, ME Bohm, HM Fadda, SR Ranmal, ... Digestive diseases and sciences 64, 1672-1678, 2019 | 71 | 2019 |
| Predictors and management of loss of response to vedolizumab in inflammatory bowel disease E Shmidt, G Kochhar, J Hartke, P Chilukuri, J Meserve, K Chaudrey, ... Inflammatory bowel diseases 24 (11), 2461-2467, 2018 | 63 | 2018 |
| Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis PS Dulai, S Singh, NV Casteele, J Meserve, A Winters, S Chablaney, ... Clinical Gastroenterology and Hepatology 18 (13), 2952-2961. e8, 2020 | 57 | 2020 |
| Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection YW Cheng, E Phelps, S Nemes, N Rogers, S Sagi, M Bohm, M El-Halabi, ... Clinical Gastroenterology and Hepatology 18 (10), 2234-2243. e1, 2020 | 55 | 2020 |
| Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn’s disease but not ulcerative colitis DM Faleck, A Winters, S Chablaney, P Shashi, J Meserve, A Weiss, ... Clinical Gastroenterology and Hepatology 17 (12), 2497-2505. e1, 2019 | 55 | 2019 |
| Association of greater intravenous volume infusion with shorter hospitalization for patients with post‐ERCP pancreatitis SV Sagi, S Schmidt, E Fogel, GA Lehman, L McHenry, S Sherman, ... Journal of gastroenterology and hepatology 29 (6), 1316-1320, 2014 | 45 | 2014 |
| Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection JR Allegretti, CR Kelly, A Grinspan, BH Mullish, J Hurtado, M Carrellas, ... Inflammatory bowel diseases 27 (9), 1371-1378, 2021 | 44 | 2021 |
| Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis AK Singal, S Sagi, YF Kuo, S Weinman European journal of gastroenterology & hepatology 23 (3), 204-209, 2011 | 42 | 2011 |
| Fecal microbiota transplantation is safe and effective in patients with Clostridioides difficile infection and cirrhosis YW Cheng, D Alhaffar, S Saha, S Khanna, M Bohm, E Phelps, M Ghabril, ... Clinical Gastroenterology and Hepatology 19 (8), 1627-1634, 2021 | 39 | 2021 |
| A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease PS Dulai, A Amiot, L Peyrin‐Biroulet, V Jairath, M Serrero, J Filippi, ... Alimentary pharmacology & therapeutics 51 (5), 553-564, 2020 | 33 | 2020 |
| Capsule endoscopy with PILLCAM ESO for detecting esophageal varices: a meta-analysis. P Guturu, SV Sagi, D Ahn, S Jaganmohan, YF Kuo, GK Sood Minerva gastroenterologica e dietologica 57 (1), 1-11, 2011 | 33 | 2011 |
| OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis M Bohm, SV Sagi, M Fischer, S Kadire, G Tran, M Rahal, S Aniwan, ... Journal of Crohn's and Colitis 12 (supplement_1), S018-S018, 2018 | 28* | 2018 |
| The real-world effectiveness and safety of ustekinumab in the treatment of Crohn's disease: results from the SUCCESS consortium AM Johnson, M Barsky, W Ahmed, S Zullow, J Galati, V Jairath, N Narula, ... Official journal of the American College of Gastroenterology| ACG 118 (2 …, 2023 | 24 | 2023 |
| Early measures of hemoconcentration and inflammation are predictive of prolonged hospitalization from post–endoscopic retrograde cholangiopancreatography pancreatitis GA Coté, SV Sagi, SE Schmidt, GA Lehman, L McHenry, E Fogel, ... Pancreas 42 (5), 850-854, 2013 | 23 | 2013 |
| Impact of a ring-fitted cap on insertion time and adenoma detection: a randomized controlled trial DK Rex, WR Kessler, SV Sagi, NA Rogers, M Fischer, ME Bohm, JM Wo, ... Gastrointestinal Endoscopy 91 (1), 115-120, 2020 | 21 | 2020 |
Sahil MittalAssistant Professor, Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TexasVerified email at bcm.edu
